J&J Achieves Strong Q4 Performance

By Patricia Miller

Jan 22, 2025

1 min read

Johnson & Johnson's Q4 results reveal strong revenue growth, driven by Darzalex sales, and an optimistic outlook for 2025 amidst strategic acquisitions.

Stock Ticker symbol of Johnson & Johnson JNJ, made of wooden cubes, on a gray background.

#What You Need To Know

Johnson & Johnson reported strong Q4 results with $22.5 billion in revenue and adjusted EPS of $2.04, driven by a 20% increase in Darzalex sales to $3.08 billion. For 2025, the company anticipates sales growth of 2.5 to 3.5% and adjusted earnings per share of $10.75 to $10.95.

J&J is bolstering its neurology portfolio with a $15 billion acquisition of Intra-Cellular Therapies Inc., which includes the Caplyta drug for bipolar depression, projected to generate $5 billion annually if successful in other neurological indications. The company aims to offset challenges from Stelara's patent expiration, while addressing legal uncertainties with an $8 billion talc settlement pending court approval.

Sign up for Investing Intel Newsletter

Get the latest news and updates from our team.

I agree to the privacy policy.

#Why This Is Important for Retail Investors

  1. Strong Financial Performance: Revenue and EPS exceeded expectations, signaling robust business operations.

  2. Growth Drivers: Rising Darzalex sales and acquiring Intra-Cellular Therapies' Caplyta drug for bipolar depression strengthen J&J’s portfolio in high-potential markets.

  3. Dividend Stability: A clear outlook for 2025 sales and earnings supports confidence in consistent shareholder returns.

  4. Patent Challenges Addressed: J&J's focus on new medicines offsets risks from Stelara's patent expiration.

  5. Talc Settlement Progress: Resolving the $8 billion lawsuit could reduce long-term legal uncertainties.

Related Articles:

Explore more on these topics:

Pharmaceuticals Biotechnology Sustainability Healthcare

Important Notice And Disclaimer

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.